Comparative Pharmacology
Head-to-head clinical analysis: AYGESTIN versus ENDOMETRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AYGESTIN versus ENDOMETRIN.
AYGESTIN vs ENDOMETRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progestin that suppresses gonadotropin secretion, inhibits ovulation, and induces endometrial changes by binding to progesterone receptors.
Progesterone is a steroid hormone that binds to progesterone receptors in the endometrium, inducing secretory changes, decreasing uterine contractility, and supporting pregnancy maintenance.
5 mg orally once daily for secondary amenorrhea; 5 mg orally once daily from day 5 to day 25 of menstrual cycle for abnormal uterine bleeding.
Vaginal tablet: 100 mg twice daily starting on day 15 of a 28-day cycle for 12 weeks.
None Documented
None Documented
Terminal half-life 5-12 hours; clinical context: requires twice-daily dosing for consistent serum levels.
Terminal elimination half-life is approximately 12-15 hours, supporting twice-daily dosing for endometrial support.
Approximately 50-80% renal as metabolites, 10-20% fecal; less than 1% unchanged.
Primarily renal (50-60% as metabolites, <10% unchanged); fecal (20-30%) via biliary excretion.
Category C
Category C
Progestin
Progestin